Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...